Technology

Updates About the Expanded Access Program for MN-166 in ALS

Published

4 months ago

June 29, 2026

Program to provide investigational drug to ALS patients who would otherwise be ineligible for clinical trials

SAN JOSE, Calif., June 29, 2026 /PRNewswire/ — WideTrial is pleased to share that the Expanded Access Program it launched in 2025, Scalable Expanded Access with Analysis of Neurofilament and other Biomarkers in ALS (SEANOBI-ALS), has reached its planned enrollment target. As a result, the program is no longer enrolling new patients.

SEANOBI-ALS was established to provide access to the investigational therapy MN-166 (ibudilast) for people living with ALS who are unable to participate in traditional clinical trials. The program is conducted in partnership with a large academic medical center and is supported by funding awarded under the ACT for ALS initiative through the National Institute of Neurological Disorders and Stroke (NINDS).

Enrollment Complete

Since enrolling its first patient in March 2025, SEANOBI-ALS has successfully enrolled 200 patients residing in 27 states through a network of 15 participating ALS clinics throughout the United States.

The strong interest in the program reflects the ongoing need for treatment access pathways for people living with ALS who do not qualify for conventional research studies due to eligibility criteria, geographic limitations, or other barriers to participation. SEANOBI-ALS swiftly reached full enrollment due to the commitment of participating sites and the strong engagement of patients and caregivers seeking access to investigational treatment options.

What Happens Next

Patients actively enrolled in SEANOBI-ALS will continue treatment and follow-up activities in accordance with the program protocol. Final patient follow-up activities are expected to conclude in early 2027, after which data collected through the program will be analyzed to support future scientific presentations and publications. WideTrial looks forward to sharing more as findings from the program become available.

Looking Ahead

Reaching 200 patients less than 13 months after first patient enrollment demonstrates both the feasibility and importance of scalable Expanded Access programs for people living with ALS.

Patients and clinics who tried but were unable to participate in SEANOBI-ALS are encouraged to continue checking with WideTrial about future EAPs, both grant-sponsored under ACT for ALS and industry-sponsored. WideTrial is now evaluating new Expanded Access opportunities in ALS and anticipates launching at least one additional large EAP in 2027.

About EAPs: Expanded Access programs (EAPs) are a type of FDA-authorized clinical trial that prioritizes experimental treatment access for patients with serious conditions who lack other meaningful, potentially disease-modifying treatment options – particularly patients who cannot get into research trials of new medicines due to inclusion/exclusion criteria or difficulty traveling to trial sites.

About this EAP: SEANOBI-ALS was designed for swift activation of participating clinics and minimal-burden on clinical staff, in comparison to research trials. This program’s secondary objective is to generate valuable data about the kinds of patients who may benefit most from the experimental treatment.

About WideTrial: WideTrial is an emerging company with the mission of making experimental treatment options accessible to all people with serious or life-threatening diseases. The team is personally aware of the devastating toll ALS takes on patients and families and is relentlessly committed to integrating well-managed EAPs into healthcare at meaningful scale.

For inquiries, please contact WideTrial via email: community@widetrial.com

Media Contact:

Shona Allen
WideTrial, Clinical Programs Director
(650) 715-7500
community@widetrial.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/updates-about-the-expanded-access-program-for-mn-166-in-als-302811403.html

SOURCE WideTrial Inc.

Technology

MiniTool ShadowMaker 5.0 Introduces Cloud Sync for Google Drive and OneDrive

Published

28 minutes ago

October 23, 2026

VANCOUVER, BC, Oct. 22, 2026 /PRNewswire/ — MiniTool® Software Limited has announced the release of MiniTool ShadowMaker 5.0, the latest version of its Windows backup and file sync software. The update introduces a new Cloud Sync feature for Google Drive and OneDrive, along with enhancements to the registration and purchase experience, interface refinements, and compatibility fixes.

New Features and Improvements in MiniTool ShadowMaker 5.0

1. Cloud Sync to Google Drive and OneDrive

MiniTool ShadowMaker 5.0 introduces Cloud Sync, allowing users to synchronize files and folders from a Windows computer to Google Drive or OneDrive. Users can choose the files and folders they want to sync and select their preferred cloud storage service as the destination.

The new feature supports one-way synchronization from a local Windows PC to cloud storage, providing an additional way to save copies of important files outside of your computer. Together with MiniTool ShadowMaker’s existing local file sync function, Cloud Sync expands the available destinations for file sync.

2. Streamlined License & Plan Management

The latest update introduces an enhanced register interface that remains easily accessible even after activation. Registered users can now effortlessly review their current plan, explore upgrade options, or update their license key anytime for a smoother user experience.

These refinements are intended to improve usability when users manage their software registration and licensing.

3. Interface Refinements and Compatibility Fixes

MiniTool ShadowMaker 5.0 includes interface improvements and fixes for certain display issues. One notable fix addresses a blurry display issue that could occur on some systems equipped with AMD GPUs.

These changes focus on resolving specific issues and improving the user experience on affected systems.

4. Additional Improvements

Beyond Cloud Sync and the changes outlined above, MiniTool ShadowMaker 5.0 includes additional interface and functionality refinements. Together, these updates further improve the software’s usability while expanding its file synchronization options.

With support for Google Drive and OneDrive, MiniTool ShadowMaker 5.0 provides Windows users with another approach to manage file copies across local and cloud storage. Users who want to synchronize files to cloud storage can download the Free Edition and explore the new capabilities.

About MiniTool ShadowMaker

MiniTool ShadowMaker is a Windows backup and file sync solution designed to help users protect their operating systems and important data. It supports backing up Windows systems, disks, partitions, files, and folders to local drives, external hard drives, shared folders, and other supported locations. Users can select specific items to back up according to their needs.

For users who need to migrate data to another drive, MiniTool ShadowMaker offers a disk cloning feature. The software also supports restoring backed-up data and creating bootable media for system recovery.

By combining backup, file synchronization, disk cloning, and restore capabilities, MiniTool ShadowMaker offers Windows users a set of tools for data protection and system recovery.

About MiniTool® Software Limited

MiniTool Software Limited is a professional software company that develops computer applications. It provides software for partition management, data recovery, data backup and sync, video editing, multimedia conversion, and screen recording for home and business users. The company is committed to developing innovative, reliable, and easy-to-use software that simplifies everyday digital tasks.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minitool-shadowmaker-5-0-introduces-cloud-sync-for-google-drive-and-onedrive-302916663.html

SOURCE MiniTool® Software Limited

Technology

Rocket Companies to Announce Third Quarter 2026 Results on October 29, 2026

Published

1 hour ago

October 22, 2026

DETROIT, Oct. 22, 2026 /PRNewswire/ — Rocket Companies, Inc. (NYSE: RKT) (“Rocket Companies” or “the Company”), the Detroit-based homeownership platform, today announced that the Company will issue its third quarter 2026 earnings on October 29, 2026. Leadership will host a conference call to discuss results at 4:30 p.m. ET on that date. A press release detailing the Company’s results will be issued prior to the call.

A live webcast of the event will be available on the “Events & Presentations” section of the Company’s Investor Relations website at ir.rocketcompanies.com. A replay of the webcast will be available on the Investor Relations website following the event.

About Rocket Companies

Founded in 1985, Rocket Companies (NYSE: RKT) is a Detroit-based homeownership platform including mortgage, real estate and personal finance businesses: Rocket Mortgage, Redfin, Rocket Close, Rocket Money and Rocket Loans.

With insights from more than 160 million calls with clients each year, more than 30 petabytes of data and a mission to Help Everyone Home, Rocket Companies is well positioned to be the destination for AI-fueled homeownership.

For more information, please visit the Company’s Corporate website or Investor Relations website.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rocket-companies-to-announce-third-quarter-2026-results-on-october-29-2026-302917496.html

SOURCE Rocket Companies, Inc.

Technology

Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister

Published

1 hour ago

October 22, 2026

SACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ — Lunai Bioworks Inc. (Nasdaq: LNAI) (the “Company”) announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2,500,000. The Company reported a stockholders’ deficit of $(9,024,946) in its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, and does not meet the alternative market value of listed securities or net income standards. Because the Company is subject to a mandatory Hearings Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B), Nasdaq staff determined to delist the Company’s securities. Trading in the Company’s common stock on Nasdaq is expected to be suspended at the opening of business on October 30, 2026.

The Company will not request a hearing. Rather than contest the staff determination, the Company’s Board of Directors approved on October 22, 2026 the voluntary withdrawal of the Company’s common stock from listing on Nasdaq under Rule 12d2-2(c) under the Securities Exchange Act of 1934, as amended. The Board took this action because of the staff determination and the Company’s financial condition, and concluded that the cost of continued listing and SEC reporting is not justified.

The Company notified Nasdaq of its intention on October 22, 2026. The Company intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about November 2, 2026, and expects the delisting to become effective on or about November 12, 2026. The Company then intends to file a Form 15 to suspend its SEC reporting obligations, to the extent it is eligible to do so. The Company’s SEC reporting obligations will continue unless and until they are terminated or suspended in accordance with the SEC’s rules.

The Company does not intend to arrange for quotation of its common stock on any over-the-counter market and cannot assure that any trading market for its common stock will exist after trading on Nasdaq is suspended.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected suspension of trading, the expected timing of the Form 25 and Form 15 filings, and the expected timing of delisting and deregistration. Actual results may differ materially due to risks and uncertainties, including Nasdaq and SEC procedures and the Company’s financial condition. The Company undertakes no obligation to update these statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-announces-receipt-of-nasdaq-determination-and-intention-to-voluntarily-delist-and-deregister-302917510.html

SOURCE Lunai Bioworks Inc.